Janux Therapeutics, Inc. (JANX) Financial Statements
Janux Therapeutics, Inc. (JANX) reported trailing twelve-month revenue of $24.0M (down 72.5% year on year) and net income of -$102.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$41.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
JANXJanux Therapeutics, Inc.Follow JANX — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Research & development | 0.03 | 0.05 | 0.05 | 0.07 | 0.13 | 0.12 | |
| Operating income | -0.03 | -0.07 | -0.07 | -0.10 | -0.16 | -0.14 | |
| Pre-tax income | -0.03 | -0.06 | -0.06 | -0.07 | -0.11 | -0.10 | |
| Income tax | — | — | — | — | 0.00 | — | |
| Net income | -0.03 | -0.06 | -0.06 | -0.07 | -0.11 | -0.10 | |
| Diluted EPS ($) | -1.39 | -1.52 | -1.32 | -1.28 | -1.83 | -1.64 | |
| Diluted shares (bn) | — | 0.041 | 0.044 | 0.054 | 0.062 | — |
USD billions · SEC XBRL
Janux Therapeutics, Inc. — questions
- What is Janux Therapeutics, Inc.'s revenue?
- $24.0M over the twelve months to 2026-06-30, down 72.5% year on year, from its 10-Q and 10-K filings.
- What is Janux Therapeutics, Inc.'s net income?
- -$102.6M over the twelve months to 2026-06-30.
- What is Janux Therapeutics, Inc.'s free cash flow?
- -$41.9M over the twelve months to 2026-06-30.
- What are Janux Therapeutics, Inc.'s diluted earnings per share?
- $-1.64 over the twelve months to 2026-06-30.
Every figure on this page comes from Janux Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.